Oblectives: The aim o{ this study was to estimate the expected cost and clinical benefits associated with the use of drotrecogin alfa (activated) (Xigris; Eli Lilly and Company; lndianapolis, lN) in the French hospital setting. Methods: The recombinant human activated PROtein C Worldwide Evaluation in Severe Sepsis (PROWESS) study results ( 1 ,271 patiènts with multiple organ failure) were adjusted to 9,948 hospital stays trom a database o{ Parisian area intensive-care units (lCUs)-the CubRea (lntensive Care Database User Group) database. The analysis features a decision tree with a probabilislic sensitivity analysis. Results: The cost per lile year gained (LYG) of drotrecogin treatment for severe sepsis with multiple organ failure (European indication) was estimated to be $1 1 ,812. At the hospital level, the drug is expected to induce an additional cost of $7,545 per treated patienl. The incremental cost-etfectiveness ratio ranges from $7,873 per LYG for patients receiving three orgân supports during ICU stay to $17,704 per LYG for patients receiving less than two organ supports. Conclusions: Drotrecogin alta (activated) is cost-etfective in the treatment of severe sepsis with multiple organ failure when added to best standard care. The cost-effectiveness of the drug increases with baseline disease severity, but it remains cost-effective for all patients when used in compliance with the European approved indication.
Severe sepsis (5) is common on French intensive-care units (ICUs), affecting 10-15 percent of admitted parients ( l;?;8). The high incidence of sepsis and its reported mortality rate of 2M5 percent ( l;3;7;8;33) are associated with substantial health care costs (9:25:26t30:.361. The resulrs of the PROWESS (recombinant human activared PROrein C Worldwide Evaluation in Severe Sepsis) trial showed that drotrecogin alfa (activated) (Xigris; Eti Lilly and Company; Indianapolis, IN) (DAA) significantly reduced mortality associated withthis condition (4) . DAA leads to an absolute risk reduction (ARR) of6.l3 percent (CIsso"--."n,, 1.86 pcrcent-10.39 percentJ), and to a relative risk (RR) of death using this drug compared with placebo of 0.80 (CIe5 o",."n,, 0.69 0.941). Regulatory authodties in the UnitedStares andEurope have approved DAA for use in different indications. In thc United States, DAA is approved for the reduction of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high riskofdeath (as determined by APACTIE II score (21) , whereas in Europe, it is approved forthe treatment ofadultpatients with severe sepsis and multiple organ failure (MOF) when added to best standard care. Although several DAA cost-effectiveness evaluations based on the USA labeling have been carried out (2;26) , few data are available regarding European labeling (31) .
MATERIALS AND METHODS

Study Design
A total of9,848 hospital stays between 1997 and 2000 were selected from the French CubRea (Intensive Care Database User Group) database (37) . These stays were associated with (i) one infected site or one positive blood culture; (ii) at least two organ failures; and (iii) length of stay of more than 24 hours. Hospital data were then added to the ICU stay data. The PROWESS results were used to estimate the effectiveness of DAA if used in CubRea patients.
The aim of the study was to determine the cost requircd to gain one additional life year among patients with severe sepsis and MOF by adding DAA to the standard care. Costs related to decreased productivity were not included to avoid double counting (they can be assessed in the effectiveness indicator) (18). No information was availablc on subsequent re-hospitalization of survivors. Only those costs relating to hospitalization during the patients' stay were computed and discounting, therefore, was unnecessary. The analytic horizon of the study was the patient's lifespan. In the baseline model, the effect was not discouffed, as this practice is controversial (14) . The CubRea database was not expected to be representative of the national patient population becausc 75 percent of the departments in ihe database were medical ICUs. A model, therefore, was constructed allowing a correction for over-representation of medical patients in thc database and extrapolation of the results of the PROWESS trial to the French population. Thc decision analysis model was created with a decision tree, all the parameters being defined by a probability densiry function. A probabilistic sensitivity analysis ( l6) was thcn completed using Data Profcssional (TreeAge Software, Inc.). StatistiÇal analyses were performed using SPSS I 1.0 for Windows (SPSS, Inc.).
Complete Cost of Hospitalization
The cost (Euros were convertedto U.S. dollan at a conversion rate of 0.98316, the 2002 rate) considered was the complete cost of hospitalization, including the di.cct (investigations, consumables, and care staff) and indirect (hotel services, laundry, pharmacy, and administration) costs of stay in an ICU and the cost of stay in hospital after intensive care. A study bascd on 2l I hospital stays (37) used micro-costing to estimate the cost of ICU hospitalization. A multiple lincar regression equation was then developed using the length of stay in intensive care, the Simplilied Acute Physiology Score (SAPS X) (24) , the Omega score (38) , and rhe sratus of the patient when leaving the ICU (deceased or alive) to predict the patient's ICU costs. The cost of non-ICU stays was estimatcd using thc daily cost for mandatory services. The length of stay is an indicator often uscd to measure hospital costs, although it should not be considered an accurate estimate of costs when uscd alone (39) . Thc SAPS II score has bcen validated as a severity index for patients with severe sepsis (23) , and the Omega score has been used predominantly to cstimate French ICU costs (12:38) .
Costs Associated with Drotrecogin Alfa (Activated)
The cost of I mg of DAA in France is cunently $46.70 excluding tax. DAA is available in 5-mg and 20-mg vials. DAA is adminishated as a continuous inftavenous infusion at 24 1.tg/kg per hour for 96 hours. Thc average weight of patients from the CubRea database was 71.6 kgi therefore, the mean treatment cost was estimated to be $7.705.50 excluding tax. The primary serious adverse event reported in the PROWESS trial was bleeding; the proponion of serious bleeding at 28 days in patients who received DAA was low and was only slightly higher than in the placebo group (3.5 percent versus 2.0 percent, p : .06) (a). Costs associ, ated with the management ofside effccts were not considered in the baseline analysis,
Drotrecogin Alfa (Activated) Eftectiveness
The primary effrcacy end point in the PROWESS study (4) was 28-day mortality after initiation of treatment. Howeyer, this criterion must be broadenedinthe context ofapharmacoeconomic evaluation (10) . The CubRea database provided ibllow-up data on patients, including deaths in ICU and palient status upon discharge from hospital.
The PROWESS study lindings showed that the drug produced consistent results regardless of patient subgroup. When only patients with MOF were considered, the RR improved from 0.80 to 0.78 (CIs:o.,"*,, 0.66-4.93) (15) . In the current evaluation, a time-dependent estimate was used instead of the RR reported in the PROWESS study. Survival of patients with severe sepsis and MOF receiving placebo and those receiving DAA in the PROWESS study was estimated using a Weibull survival function (42) . The RR used in the model is the ratio of these two survival functions and is consequently a function of the mean length of survival of the paticnts (Figure 1 ). It is assumed that risk is reduccd in the ICU and also in the hospital wards that follow.
Life Expectancy
The unit of effectiveness haditionally used in pharmaco-eÇonomic evaluations isthe quality adjustedlife year (QALY) (ll). As no French cohon study has been conducted to date in ICU patients surviving severe sepsis, there are no data available regarding the life expectancy (LE) or quality of life of this population. However, the study by Quanin et al. (34) suggests that sepsis reduces thc LE of survivors. Accordingly, the survivors'LE was computed as follows: ûrst, the Mccab€ classification was used to take account of short-term fatal comorbidities (27) . Patients without serious concomitant diseases werç then allocated the ageand sexspecific LE ofthe general population using French life tables from 1997 to 2000. Finally, the LE of survivors was assumed to b€ half of that estimaled for the general population, as described by Quartin et al. (34) . As the relative mortality risk for patients with severe sepsis decreases with time and is not significantly different after 5 years, rhis study may underestimate the Datient's LE.
Studies evaluating quality of life after ICU stay have reported a range of coeffrcients from 0.6 to >0.8 (2;19;20;26) . The lowest coeflicient was used here. as in the Canadian DAA cost-effectiveness study (26) .
Stratification Criteria
The decision tree stratified patients according to their admission category (medical, scheduled, or unscheduled surgery), origin of admission offo the ICU (community, ward, other institution), and health care profile. The first ofthese criteria is recognized as a factor linked to mortality (24), the second is an indirect indicator of early infection, and the third follows a medico-economic classitcation of patients proposed by a group ofFrench mediÇal societies (French Society forAnaesthesia and Intensive Care, French Language Intensive Care Society and the National Academy for Public Health) (29) . This classification groups patients accordiog to the treatment administered for respiratory, circulatory, and renal failure (defined by the autho.s as organ supports): the duration of support (estimated from the Omega score); and the risk of death (estimated fiom the SAPS II score). The clinical and economic relevance of this classification has been validated rn other studies (13:17) . Death can occur in rhe ICU or in the hospital after leaving the ICU. The proponion of medical patients used in the study was the only variable that was not obtained from the CubRea database: published findings indicate that this proportion (0.78) was overestimated in the database (l;7;23). A medical admission proportion of 0.70 was used in the decision tree instcac. 
Sensitivity Analysis
A sensitivity analysis was used to estimate the stability of the conclusions of the model assuming variability of key parameters. A simple one-way sensitivity analysis was first completed to assess the effects ofthe model's assumptions. A probabilistic sensitivity analysis using second-order Monte Carlo simulation was then performed (16) . A Monte Carlo simulation implies the sampling of any stochastic parameter of the model from its particular probability density function and the estimation of the model outcomes using the sarnpled parameters instead of their deterministic value. A total of 5,000 random draws of the 385 model parameters were generated.
RESULTS
Patient Characteristics
The PROWESS and CubRea patient characteristics are shown in Table l . The French patients differ from those in the PROWESS trial with respecr to organ failure distribution but are relatively similar in terms of renal, circulatory, and respratory support (15) . It is more diflicult to compare the different severity scores used in PROWESS and CubRea. Both the APACHE II and SAPS II scorcs. however. allow the calculation of a mortality risk, which was higher for patients in the PROWESS trial (0.57 versus 0.48). Assuming both scores have a similar predictive performance (28), patients in the PROWESS trial can be considered to be more severely ill than those in the CubRea database, This assumption requires careful consideration, as the predictive power ofthese scores has been questioned.
Standard Care
All patient characteristics (except for LE, which was determined from the assumptions described above) were estimated from the CubReadatabase afteradjusting fornon-surgical admissions ( Table 2 ). The cost of care increased considerably with the number of organ supports. The majority of CubRea database paticnts required respiratory and circulatory support (56.9 perÇent of stays). The mean hospital length of survival (in ICU and post-ICU) ranged from 26 to 3l days, depending on patient category. Hence, the length ofstay was close to the 28-day threshold used in the PROWESS trial. The estimared cost per patient in this study, $31,289, is similar to the cost estimated in thc Canadian (26) ($32,950 for all patienls and 535,104 for those with an APACHE II score of >25) and American (2) ($32,066 for all patients) studies. However, these costs are higher than those estimated in other foreign studies (3;25;30:36) and close to those reported for French patients (9) .
Cost-Effectiveness Analysis
The incremental cost and effectiveness, estimated according to patient admission category and number of organ supports, are shown in Table 3 . The resulting incremental costeffectiveness ratios (ICERs) were calculated in dollars per life year gained (LYG) and per QAIY An average of$11,812 was spent to gain 1 additional life year using DAA. This ligure showed little change depending on the admission category; medical patients requùed $11,507 per LYG versus $12,573 per LYG for surgical patients. Medical patients actually had a higher mortality risk combined with a younger age in the CubRea database ( Table 2 ). The cost per LYG was lowest among patients requiring the most suppon: the ICER for patients requiring renal, respiratory, and circulatory support was $7,873 per LYG, compared with $12,942 per LYG for two of the three organ supports and $17,704 per LYG if the patient received fewer than two of the three organ supports. These patients were less cost-effective than the others because oftheir lower mortality risk (26.6 percent compared Cost-etfectiveness of drotrecogin alfa with 45.7 percent and 74.1 percent for patients with two and three organ supports, respectively). Because thc effect of DAA is assessed using an RR of death, the most costeffective patients are those with a higher mortality risk. Other cost-effectiveness factors, such as LE of the survivors, play a secondary role.
Sensitivity Analysis
The deterministic model shows that DAA is cost-effective in the treatment of severe sepsis with MOF. Table 4 summarizes the one-way sensitivity analysis of ICER to key variables. Using the upper (0.93) and lower (0.66) bounds of the 95 percent confidence interval computed for the RR of death for patients with MOF in the PROWESS trial Jl5l, the ICER ranges fiom $6,450 to $33,894 per LYG. The ICER in the model is sensitive to the value of RR Using the PROWESS ARR rather than RR, a ratio of $14,413 per LYG is obtained. As ihe mortality rate reported in the CubRea database was higher than that observed in the PROWESS trial (Iable 1), using the RR inevitably leads to a higher ARR. There currently are no guidelines regarding which estimator, ARR o. RR, to use in pharmaco-economic evaluations (35) . Nevertheless. the choice made has little effect on the overall ratio. There is little change in the ICER when the mean body weight increases from 65 to 75 kg (from $11,065 to $12,559 per LYG).
Another consideration is the cost of treating adverse events related to treatment; it was assumed to be negligible in the current study.Ifthis cost increases on average from $0per patient to $492 (€500) per patient, the ratio increases from $11,812 to $12,581 per LYG. When an annual discounting rate of 5 percent for future effects is used, the ICER remains below the most common decision thresholds ($19,961 per LYG, $33,268 per Q N,Y). (22:40) A probabilistic sensitivity analysis was conducted to account for the uncertainty related to all of the parameters (6) . A cost-effectiveness acceptability curve (41l) is shown in Figure 2 . This curve reports the probabilily that the ICER of teatment is below any decisional theshold. Assuming a willingness to pay of $50,000 per QALY, this probability is 85 percent (71 percent for patients with less than two organ PROWESS trial (4) . Consequenrly, the probability of costeffectiyeness cannot exceed 95 percent, even for an infinite willingness to pay.
DISCUSSION
This study, which was conducted in conformity with intematronal recommendations (43) , shows that the ICER for DAA lies within the range considered to be acceptable for interventions (22;40) . Although this ratio is relatively sçnsitive to some of the assumptions in thc model, such as the ex, pected effect of the drug on monality (measurcd by its RR) and in particular to the discount rate chosen ('fable 4), the rncremental ratio does not exceed the conventional threshold of $50,000 per QALY until the RR rises to more than 0.92. Because RR was used to model the effect of reatment instead of ARR, the drug was found to be morc costeffective in patients with a high risk of mortality. This effect is reduced in the current study, as the RR was adjusted for the length of survival of patients and is lower than that reported in the PROWESS study (0.82 versus 0.78) (15) . Moreover, using an ARR requires populations with similar mortality rates, a condition only partially met in French ICUS (Table I ) .
The coefficients of the equation used to estimate thc cost of conventional care were estimated from a population of ICU patients, and it is possible that estimation among severely septic patients alone would have lçd to a different equation. However, the mean treatment cost of a patient in the model rcmains similar to that estimated in other studies (2;26;30) . The otherestimatcs in this model were also consistent with other studies. Using a discount rate of5 percent, the LYC,life year gained; RR. rciative risk; LOS, leDglh ol stay; ARR, absolure isk reduction. suppons, 82 percent for those with two organ supports, and 9l percent for those with three organ suppons). Following Neyman's interpretation ofhypothesis testing (32) , the model assumes that the probability of DAA being ineffective is 5 percent, the type I enor probability chosen in the ovçrall cost-effectiveness ratio reported in this study was $33,268 per QALY for patients with severe sepsis and MOF (Table 4 ), a result equivalent to the ICERs estimated for patients with APACIIE II scores of :25 in other studies ($32,872 per QALY in the Canadian study and $27,400 per QAIY in the American study). These studies were based on approved U.S. indications. Although the American and European indications for DAA are different, cost-effectiveness estimates remain similar. This Ênding suggesls that the European indication based on organ failure and the Amedcan indication in terms ofrisk ofdeath (measured by the APACHE II score) may lead to a similar cost-effectiveness.
In thc current model. French patients surviving severe sepsis with MOF can expect to live for an average of 7.9 years ( Table 2 ). Canadian patients surviving severe sepsis (regardless ofthe number of organ failures) can expectto live for an average of 8.1 years (26) . The Canadian calculation was based on a 3-year long cohon study and on national LE tables for the subsequent years, and could be consideredto be more reliable than ours. An Amcrican study, using the same calculation method as the current one, reports an average LE of 12.3 years lbr patients surviving severe sepsis (2) .
POLICY IMPLICATIONS
Our model, based on the European indication for the drug, produces estimates that may be more appropdate in the European context. According to our results, DAA can be considered cost-effective in the European indication. Alrhough severely ill patients have more attractive ICERs, it would be unethical to treat only some subgroups ofpatients, at leasi on thc basis of the number of organ supports received, because even the least attractive cost-effeclive ratio remains below the acceptable threshold. However, treating the patients with this new drug will increase ICUs expenses. In France, this problem was taken into account by reporting DAA'S cost separately, the drug being fully and directly reimbursed by the sickness funds. coNcLusroN It can be concluded that DAA is cost-effective for the lreatment of adult patients when used in the European indication. An estimate of the cost-effectiveness of this new treatment is provided, which is more suitable for European countries, and more specifically for France.
Despite the differences in the patient population considered and the assessment methods used. these results are concordant with those described previously in other studies. More data on the long-term survival and quality of life of patients, as well as on the effect oftreatment on cunent practices, would be valuable to havc a better idea of the impact of the drus.
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